KLI
ONCT

Kelman-Lazarov Inc’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Kelman-Lazarov Inc’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-119
Closed -$88K – 127
2017
Q2 		$88K Buy
+119
New +$73K 0.05% 116
2017
Q1 		– Sell
-11
Closed -$8.13K – 269
2016
Q4 		$8.13K Sell
11
-41
-79% -$43.8K ﹤0.01% 263
2016
Q3 		$54.9K Buy
52
+9
+21% +$7.85K 0.03% 171
2016
Q2 		$33.1K Hold
43
– – 0.02% 195
2016
Q1 		$34K Buy
+43
New +$37.3K 0.02% 210

Other funds holding ONCT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
FHA
First Horizon Advisors Memphis, Tennessee $3.85B AUM 16.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kelman-Lazarov Inc's ONCT Position: Q3 2017 in Review

Kelman-Lazarov Inc sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2017, closing a stake of 119 shares — an estimated $88K sold.

Kelman-Lazarov Inc first reported a position in ONCT in Q1 2016 and held it in 5 quarters. The position peaked at $88K in Q2 2017. 20 funds tracked by Wall St. Rank hold ONCT as of Q3 2017.

  • Kelman-Lazarov Inc reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Kelman-Lazarov Inc sold 119 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2017, an estimated $88K.
  • Kelman-Lazarov Inc first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2016 and held it in 5 quarters.
  • Kelman-Lazarov Inc's Oncternal Therapeutics, Inc. Common Stock position peaked at $88K in Q2 2017.
  • 20 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2017.

Based on Kelman-Lazarov Inc's 13F filing for Q3 2017, filed 5 Oct 2017.